Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
Miyamoto
Hiroshi
H
Department of Pathology, University of Rochester Medical Center, NY 14642, USA.
Messing
Edward M
EM
Chang
Chawnshang
C
D000368:Aged; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen